These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8856289)

  • 1. High risk of retinal damage by desferrioxamine in dialysis patients.
    Albalate M; Velasco L; Ortiz A; Monzú B; Casado S; Caramelo C
    Nephron; 1996; 73(4):726-7. PubMed ID: 8856289
    [No Abstract]   [Full Text] [Related]  

  • 2. [Poisoning of retinal pigment epithelium by deferoxamine. A case report].
    Charton N; Sahel JA; Flament J
    Bull Soc Ophtalmol Fr; 1990; 90(6-7):599-602. PubMed ID: 2225255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P
    Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
    [No Abstract]   [Full Text] [Related]  

  • 4. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
    Cases A; Kelly J; Sabater F; Torras A; Griño MC; Lopez-Pedret J; Revert L
    Nephron; 1990; 56(1):19-23. PubMed ID: 2234245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of osteocalcin fragments in the serum of dialyzed patients during desferrioxamine treatment.
    Gerakis A; Apostolou T; Billis A
    Nephron; 1995; 71(1):124. PubMed ID: 8538842
    [No Abstract]   [Full Text] [Related]  

  • 6. Desferrioxamine related maculopathy: a case report.
    Arora A; Wren S; Gregory Evans K
    Am J Hematol; 2004 Aug; 76(4):386-8. PubMed ID: 15282675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular changes in patients undergoing long-term desferrioxamine treatment.
    Arden GB; Wonke B; Kennedy C; Huehns ER
    Br J Ophthalmol; 1984 Dec; 68(12):873-7. PubMed ID: 6509007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal Aeromonas hydrophila bacteremia in a hemodialysis patient treated with deferoxamine.
    Lin SH; Shieh SD; Lin YF; De Brauwer E; Van Landuyt HW; Gordts B; Boelaert JR
    Am J Kidney Dis; 1996 May; 27(5):733-5. PubMed ID: 8629637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retinopathy caused by desferrioxamine].
    Sánchez Dalmau BF; Vela Payán MD
    Med Clin (Barc); 1996 Nov; 107(16):636. PubMed ID: 9064398
    [No Abstract]   [Full Text] [Related]  

  • 10. Benefits of parenteral deferoxamine for acute iron poisoning.
    Tenenbein M
    J Toxicol Clin Toxicol; 1996; 34(5):485-9. PubMed ID: 8800185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.
    Di Nicola M; Barteselli G; Dell'Arti L; Ratiglia R; Viola F
    Biomed Res Int; 2015; 2015():249617. PubMed ID: 26167477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidotes: benefits and risks.
    Proudfoot AT
    Toxicol Lett; 1995 Dec; 82-83():779-83. PubMed ID: 8597142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
    Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side-effects of desferrioxamine in dialysis patients.
    Boelaert JR; de Locht M
    Nephrol Dial Transplant; 1993; 8 Suppl 1():43-6. PubMed ID: 8389020
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pigmentary changes of the retina in dialysis patients treated with deferoxamine].
    Mathys B; Baeck A; Verougstraete C; Verstappen A; D'Haene M; Zanen A
    Bull Soc Belge Ophtalmol; 1988; 229():49-60. PubMed ID: 3273254
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 17. Risks of parenteral deferoxamine for acute iron poisoning.
    Howland MA
    J Toxicol Clin Toxicol; 1996; 34(5):491-7. PubMed ID: 8800186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis].
    Martín C; Lens XM; Prieto A; Alonso R; Correa B; Arcocha V; Soto A
    An Otorrinolaringol Ibero Am; 1994; 21(2):193-8. PubMed ID: 8209972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desferrioxamine in the management of dialysis hemosiderosis.
    Krumlovsky FA
    Int J Artif Organs; 1982 Jul; 5(4):223-5. PubMed ID: 7118282
    [No Abstract]   [Full Text] [Related]  

  • 20. Dialysis associated mucormycosis and desferrioxamine treatment: a case report with review of the role of oxygen radicals.
    Seeverens HJ; Tijhuis GJ; Ruijs GJ; Kazzaz BA; Kauffmann RH
    Neth J Med; 1992 Dec; 41(5-6):275-9. PubMed ID: 1494406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.